$0.65
2.04% day before yesterday
Nasdaq, Dec 27, 10:04 pm CET
ISIN
US70387R1068
Symbol
PAVM

PAVmed, Inc. Stock price

$0.65
-0.29 31.06% 1M
-0.12 15.48% 6M
-2.90 81.75% YTD
-2.89 81.66% 1Y
-36.33 98.25% 3Y
-14.22 95.64% 5Y
-167.43 99.61% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.01 2.04%
ISIN
US70387R1068
Symbol
PAVM
Sector

Key metrics

Market capitalization $7.17m
Enterprise Value $40.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 9.94
P/S ratio (TTM) P/S ratio 1.78
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 166.27%
Revenue (TTM) Revenue $4.03m
EBIT (operating result TTM) EBIT $-55.68m
Free Cash Flow (TTM) Free Cash Flow $-45.76m
Cash position $770.00k
EPS (TTM) EPS $-4.31
P/E forward 0.26
P/S forward 2.38
EV/Sales forward 13.29
Short interest 3.09%
Show more

Is PAVmed, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

PAVmed, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a PAVmed, Inc. forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a PAVmed, Inc. forecast:

Buy
67%
Hold
33%

Financial data from PAVmed, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4.03 4.03
165% 165%
100%
- Direct Costs 8.26 8.26
12% 12%
205%
-4.22 -4.22
46% 46%
-105%
- Selling and Administrative Expenses 41 41
15% 15%
1,015%
- Research and Development Expense 8.72 8.72
51% 51%
216%
-54 -54
27% 27%
-1,336%
- Depreciation and Amortization 1.85 1.85
41% 41%
46%
EBIT (Operating Income) EBIT -56 -56
28% 28%
-1,382%
Net Profit 24 24
134% 134%
603%

In millions USD.

Don't miss a Thing! We will send you all news about PAVmed, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PAVmed, Inc. Stock News

Neutral
PRNewsWire
6 days ago
NEW YORK , Dec. 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it had received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company was eligible for ...
Neutral
PRNewsWire
10 days ago
Partnership launched with fully-contracted #CheckYourFoodTube Precancer Testing Event for Tuscaloosa firefighters NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into a strategic partnershi...
Neutral
PRNewsWire
18 days ago
Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard esophageal precancer testing NEW YORK , Dec. 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed I...
More PAVmed, Inc. News

Company Profile

PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The firm conducts its operations in four divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy and Emerging Innovations. The GI Health division consists of Edouard Esophageal DNA Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. The Minimally Invasive Interventions division consists of CarpX, which is a patented, single-use disposable, minimally invasive device designed to treat carpal tunnel syndrome. The Infusion Therapy division consists of PortIO, which is a novel, patented, implantable, intraosseous vascular medical device; and NextFlo, which is designed to deliver gravity-driven infusions independent of the height of the IV bag. The Emerging Innovations division refers to a diversified and expanding portfolio of innovative products designed to address unmet clinical needs across a broad range of clinical conditions. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Head office United States
CEO Lishan Aklog
Employees 107
Founded 2014
Website www.pavmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today